Abstract
Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega-3 fatty acids. If fenofibate-related side effects occur, or a statin is required to control low-density lipoprotein-cholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment.
MeSH terms
-
Adult
-
Aged
-
Bexarotene
-
Contraindications
-
Drug Therapy, Combination
-
Fatty Acids, Omega-3 / administration & dosage*
-
Fatty Acids, Omega-3 / metabolism
-
Female
-
Fenofibrate / therapeutic use
-
Humans
-
Hypertriglyceridemia / chemically induced*
-
Hypertriglyceridemia / metabolism
-
Hypertriglyceridemia / therapy
-
Hypolipidemic Agents / therapeutic use
-
Lymphoma, T-Cell, Cutaneous / drug therapy*
-
Lymphoma, T-Cell, Cutaneous / metabolism
-
Male
-
Middle Aged
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / metabolism
-
Tetrahydronaphthalenes / adverse effects*
-
Tetrahydronaphthalenes / therapeutic use
-
Treatment Outcome
Substances
-
Fatty Acids, Omega-3
-
Hypolipidemic Agents
-
Tetrahydronaphthalenes
-
Bexarotene
-
Fenofibrate